



Myriad Genetics, Inc.
Investor Relations Department
320 Wakara Way
Salt Lake City, UT 84108
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: MYGN

Last Trade:	32.81
Trade Time:	4:00 PM ET Feb 16, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	17.50 - 41.57
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Why Invest in Myriad Genetics

Myriad's 9 molecular diagnostic tests provide a preeminent market position today; with revenue up 23% in FY2012 our 13 innovative pipeline tests will ensure Myriad's continued growth for the future. Th... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 15, 2018

[JAMA Oncology Publication Demonstrates EndoPredict® \(EPclin\) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer](#)

Feb 7, 2018

[Myriad's myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation](#)

Feb 6, 2018

[Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results](#)

Jan 25, 2018

[Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018](#)

Jan 22, 2018

[Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Aug 9, 2017

[Annual Report \(10-K\)](#)

Oct 11, 2016

[Proxy Statement \(DEF 14A\)](#)

Feb 7, 2018

[Quarterly Report \(10-Q\)](#)

Nov 8, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)